You are here: Industry Insights > Roche

News List

Study: Roche's emicizumab cuts bleed rate by 87 percent in patients with haemophilia A firstwordpharma
June 27, 2017
Roche's emicizumab cuts bleed rate by 87 percent in patients with haemophilia A
Roche Receives FDA Approval for Fourth-Generation HIV Combination Antigen-Antibody Assay americanpharmaceuticalreview
June 27, 2017
Roche announced its fourth-generation HIV combination antigen-antibody assay, the Elecsys HIV combi PT assay, has received FDA PMA approval from the U.S. Food and Drug Administration (FDA).
Roche, Pfizer and Aspen under investigation over cancer drug pricing pharmaceutical-technology
June 21, 2017
The Competition Commission of South Africa has initiated separate investigations against three global pharmaceutical companies over suspected excessive pricing of cancer medicines.
Roche's employee-driven philanthropic campaign sets new record worldpharmanews
June 16, 2017
Roche's employee-driven philanthropic campaign sets new record
Roche's employee-driven philanthropic campaign sets new record worldpharmanews
June 15, 2017
Today, Roche (SIX: RO, ROG; OTCQX: RHHBY) employees from 145 company sites in 70 countries participate in the 14th Roche Children's Walk.
Puma gains as Roche breast cancer combo disappoints pharmaphorum
June 07, 2017
Few would have predicted that little biotech Puma would get the advantage over mighty Roche in the race to develop a new breast cancer drug.
FDA approves Roche’s lung cancer companion diagnostic europeanpharmaceuticalreview
June 07, 2017
The US Food and Drug Administration (FDA) have approved Roche’s VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible ...
FDA grants approval for Roche's ALK test as CDx for Zykadia biospectrumasia
June 02, 2017
The VENTANA ALK (D5F3) Assay is the only immunohistochemistry (IHC) test approved by the FDA as a companion diagnostic for ZYKADIA
New data at ATS add to the body of evidence for Roche's Esbriet (pirfenidone) in idiopathic pulmonar worldpharmanews
May 27, 2017
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new retrospective data analyses for Esbriet® (pirfenidone) in idiopathic pulmonary fibrosis (IPF) that were presented at the American Thoracic Society (ATS) 2017 International Conference.
Roche's Tecentriq fails to increase survival in advanced bladder cancer study firstwordpharma
May 11, 2017
Roche announced Wednesday that the Phase III IMvigor211 study of Tecentriq (atezolizumab) in people with locally advanced or metastatic urothelial cancer (mUC) whose disease progressed during or after treatment...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page